Milestone Pharmaceuticals Inc.

NasdaqGS:MIST Rapporto sulle azioni

Cap. di mercato: US$99.3m

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Milestone Pharmaceuticals Gestione

Gestione criteri di controllo 3/4

Milestone Pharmaceuticals' Il CEO è Joe Oliveto, nominato in Mar2017, e ha un mandato di 7.42 anni. la retribuzione annua totale è $ 1.98M, composta da 30.4% di stipendio e 69.6% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.43% delle azioni della società, per un valore di $ 382.14K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 4.4 anni e 6.2 anni.

Informazioni chiave

Joe Oliveto

Amministratore delegato

US$2.0m

Compenso totale

Percentuale dello stipendio del CEO30.4%
Mandato del CEO7.6yrs
Proprietà del CEO0.4%
Durata media del management4.5yrs
Durata media del Consiglio di amministrazione5.5yrs

Aggiornamenti recenti sulla gestione

Here's Why Shareholders Should Examine Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) CEO Compensation Package More Closely

Jun 07
Here's Why Shareholders Should Examine Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) CEO Compensation Package More Closely

Recent updates

Here's Why Shareholders Should Examine Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) CEO Compensation Package More Closely

Jun 07
Here's Why Shareholders Should Examine Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) CEO Compensation Package More Closely

Is Milestone Pharmaceuticals (NASDAQ:MIST) A Risky Investment?

Sep 13
Is Milestone Pharmaceuticals (NASDAQ:MIST) A Risky Investment?

We're Keeping An Eye On Milestone Pharmaceuticals' (NASDAQ:MIST) Cash Burn Rate

Mar 07
We're Keeping An Eye On Milestone Pharmaceuticals' (NASDAQ:MIST) Cash Burn Rate

We're Keeping An Eye On Milestone Pharmaceuticals' (NASDAQ:MIST) Cash Burn Rate

Oct 15
We're Keeping An Eye On Milestone Pharmaceuticals' (NASDAQ:MIST) Cash Burn Rate

We Think Milestone Pharmaceuticals (NASDAQ:MIST) Can Afford To Drive Business Growth

Jun 24
We Think Milestone Pharmaceuticals (NASDAQ:MIST) Can Afford To Drive Business Growth

We're Hopeful That Milestone Pharmaceuticals (NASDAQ:MIST) Will Use Its Cash Wisely

Feb 25
We're Hopeful That Milestone Pharmaceuticals (NASDAQ:MIST) Will Use Its Cash Wisely

We're Interested To See How Milestone Pharmaceuticals (NASDAQ:MIST) Uses Its Cash Hoard To Grow

Aug 25
We're Interested To See How Milestone Pharmaceuticals (NASDAQ:MIST) Uses Its Cash Hoard To Grow

Companies Like Milestone Pharmaceuticals (NASDAQ:MIST) Are In A Position To Invest In Growth

Apr 02
Companies Like Milestone Pharmaceuticals (NASDAQ:MIST) Are In A Position To Invest In Growth

What You Need To Know About Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) Investor Composition

Jan 15
What You Need To Know About Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) Investor Composition

First patient enrolled in Milestone Pharmaceuticals' late-stage study of etripamil in PSVT

Nov 18

Milestone Pharmaceuticals EPS beats by $0.09

Nov 13

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Joe Oliveto rispetto agli utili di Milestone Pharmaceuticals?
DataCompenso totaleStipendioGuadagni aziendali
Jun 30 2024n/an/a

-US$48m

Mar 31 2024n/an/a

-US$55m

Dec 31 2023US$2mUS$602k

-US$60m

Sep 30 2023n/an/a

-US$59m

Jun 30 2023n/an/a

-US$59m

Mar 31 2023n/an/a

-US$59m

Dec 31 2022US$3mUS$584k

-US$58m

Sep 30 2022n/an/a

-US$62m

Jun 30 2022n/an/a

-US$62m

Mar 31 2022n/an/a

-US$44m

Dec 31 2021US$4mUS$509k

-US$43m

Sep 30 2021n/an/a

-US$35m

Jun 30 2021n/an/a

-US$32m

Mar 31 2021n/an/a

-US$46m

Dec 31 2020US$4mUS$470k

-US$50m

Sep 30 2020n/an/a

-US$60m

Jun 30 2020n/an/a

-US$60m

Mar 31 2020n/an/a

-US$61m

Dec 31 2019US$785kUS$458k

-US$55m

Sep 30 2019n/an/a

-US$47m

Jun 30 2019n/an/a

-US$40m

Mar 31 2019n/an/a

-US$29m

Dec 31 2018US$1mUS$360k

-US$23m

Dec 31 2017US$851kUS$364k

-US$8m

Compensazione vs Mercato: La retribuzione totale di Joe ($USD 1.98M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 681.57K ).

Compensazione vs guadagni: La retribuzione di Joe è stata coerente con le performance aziendali dell'ultimo anno.


AMMINISTRATORE DELEGATO

Joe Oliveto (56 yo)

7.6yrs

Mandato

US$1,978,092

Compensazione

Mr. Joseph G. Oliveto, also known as Joe, M.B.A. has been Chief Executive Officer and President of Milestone Pharmaceuticals Inc. March 2017 and has been its Director since July 2017. Mr. Oliveto served as...


Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Joseph Oliveto
CEO, President & Director7.6yrsUS$1.98m0.43%
$ 427.8k
Amit Hasija
CFO & Executive VP of Corporate Development5.1yrsUS$1.01m0.029%
$ 28.8k
David Bharucha
Chief Medical Officer2.7yrsUS$1.22m0.023%
$ 22.7k
Philippe Douville
Founderno dataNessun datoNessun dato
Jeffrey Nelson
Chief Operating Officer4.3yrsNessun datoNessun dato
Kim Fox
Vice President of Communications1.1yrsNessun datoNessun dato
Philip Sager
Chief Medical Advisor & Member of the Scientific Advisory Board4.8yrsNessun datoNessun dato
Guy Rousseau
SVP of Regulatory Affairs and Quality Managementno dataNessun datoNessun dato
Lorenz Muller
Chief Commercial Officer7yrsUS$645.72k0.20%
$ 200.1k
Anita Holz
VP & Head of Medical Affairs2.2yrsNessun datoNessun dato

4.5yrs

Durata media

60yo

Età media

Gestione esperta: Il team dirigenziale di MIST è considerato esperto (durata media dell'incarico 4.4 anni).


Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Joseph Oliveto
CEO, President & Director7.3yrsUS$1.98m0.43%
$ 427.8k
Philippe Douville
Founder4.8yrsNessun datoNessun dato
Philip Sager
Chief Medical Advisor & Member of the Scientific Advisory Boardno dataNessun datoNessun dato
Harry Leighton
Member of the Scientific Advisory Boardno dataNessun datoNessun dato
Daniel Omstead
Observer7.2yrsNessun datoNessun dato
Harry Kopelman
Member of the Scientific Advisory Boardno dataNessun datoNessun dato
Peter Kowey
Member of the Scientific Advisory Boardno dataNessun datoNessun dato
John DiMarco
Member of the Scientific Advisory Boardno dataNessun datoNessun dato
Paul Dorian
Member of the Scientific Advisory Boardno dataNessun datoNessun dato
Michael Tomsicek
Independent Non-Executive Director5.5yrsUS$153.27k0.023%
$ 22.5k
John Camm
Member of the Scientific Advisory Boardno dataNessun datoNessun dato
Robert Wills
Independent Chairman of the Board4yrsUS$176.77k0.023%
$ 22.5k

5.5yrs

Durata media

68yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di MIST sono considerati esperti (durata media dell'incarico 6.2 anni).